A Clinical Study of TQB3824 in Subjects With Advanced Cancer
Primary Purpose
Advanced Cancer
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQB3824 tablets
Sponsored by

About this trial
This is an interventional treatment trial for Advanced Cancer
Eligibility Criteria
Inclusion Criteria:
- Understood and signed an informed consent form;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
- Life expectancy >=3 months;
- Progressed after standard treatment or no standard treatment with an established survival benefit is available;
- Adequate organ/system function;
- Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.
Exclusion Criteria:
- Diagnosed and/or treated additional malignancy within 3 years before the first dose;
- With factors affecting oral medication;
- Toxicity that is >=Grade 2 caused by previous cancer therapy;
- Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the first dose;
- Arterial thromboembolism and/or venous thromboembolism within 6 months;
- A history of psychotropic drug abuse or have a mental disorder;
- Any severe and/or uncontrolled disease;
- Has received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks before the first dose;
- Has received Chinese patent medicines with anti-tumor indications that National Medical Products Administration (NMPA) approved within 2 weeks before the first dose;
- Has received CDC7 inhibitors;
- Pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage;
- Brain metastases ;
- Has participated in other clinical studies within 4 weeks before the first dose;
- According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Sites / Locations
- Tianjin Medical University Cancer Institution & HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TQB3824 tablets
Arm Description
TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
Outcomes
Primary Outcome Measures
Dose-limiting toxicity (DLT)
DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Maximum Tolerated Dose (MTD)
The maximum Dose at which less than 33% subjects experiencing DLT
Recommended Phase II Dose (RP2D)
RP2D will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
Secondary Outcome Measures
Area under the plasma concentration-time curve (AUC)
Concentration Uncer Curve
Maximum (peak) plasma drug concentration (Cmax)
Maximum plasma concentration of drug
Time to reach maximum(peak )plasma concentration following drug administration (Tmax)
Time to Reach the Maximum Plasma Concentration
Overall response rate (ORR)
The sum of percentage of participants with complete response rate and partial response rate
Disease Control Rate (DCR )
percentage of participants with complete response (CR), partial response (PR) plus stable disease (SD)
Duration of Response (DOR)
the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression
Progression-free survival (PFS)
Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first
Overall survival (OS)
the time from start of study treatment to date of death due to any cause
Full Information
NCT ID
NCT05028218
First Posted
August 25, 2021
Last Updated
September 18, 2021
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT05028218
Brief Title
A Clinical Study of TQB3824 in Subjects With Advanced Cancer
Official Title
A Phase I Study to Evaluate the Safety and Pharmacokinetics of TQB3824 in Subjects With Advanced Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Recruiting
Study Start Date
August 31, 2021 (Actual)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
TQB3824 blocks function of a specific protein called Cell Division Cycle 7 (CDC7) kinase in the human body, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways. This study will evaluate the safety, tolerability and pharmacokinetics of TQB3824.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
65 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TQB3824 tablets
Arm Type
Experimental
Arm Description
TQB3824 tablets orally administrated orally on Days 1-21 of each 21-day treatment cycle. Dose escalation of TQB3824 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
Intervention Type
Drug
Intervention Name(s)
TQB3824 tablets
Intervention Description
TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.
Primary Outcome Measure Information:
Title
Dose-limiting toxicity (DLT)
Description
DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Time Frame
up to 18 months
Title
Maximum Tolerated Dose (MTD)
Description
The maximum Dose at which less than 33% subjects experiencing DLT
Time Frame
up to 18 months
Title
Recommended Phase II Dose (RP2D)
Description
RP2D will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data
Time Frame
up to 18 months
Secondary Outcome Measure Information:
Title
Area under the plasma concentration-time curve (AUC)
Description
Concentration Uncer Curve
Time Frame
up to 18 months
Title
Maximum (peak) plasma drug concentration (Cmax)
Description
Maximum plasma concentration of drug
Time Frame
up to 18 months
Title
Time to reach maximum(peak )plasma concentration following drug administration (Tmax)
Description
Time to Reach the Maximum Plasma Concentration
Time Frame
up to 18 months
Title
Overall response rate (ORR)
Description
The sum of percentage of participants with complete response rate and partial response rate
Time Frame
Baseline up to 12 months
Title
Disease Control Rate (DCR )
Description
percentage of participants with complete response (CR), partial response (PR) plus stable disease (SD)
Time Frame
Baseline up to 12 months
Title
Duration of Response (DOR)
Description
the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression
Time Frame
Baseline up to 12 months
Title
Progression-free survival (PFS)
Description
Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first
Time Frame
Baseline up to 12 months
Title
Overall survival (OS)
Description
the time from start of study treatment to date of death due to any cause
Time Frame
Baseline up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Understood and signed an informed consent form;
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
Life expectancy >=3 months;
Progressed after standard treatment or no standard treatment with an established survival benefit is available;
Adequate organ/system function;
Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped.
Exclusion Criteria:
Diagnosed and/or treated additional malignancy within 3 years before the first dose;
With factors affecting oral medication;
Toxicity that is >=Grade 2 caused by previous cancer therapy;
Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the first dose;
Arterial thromboembolism and/or venous thromboembolism within 6 months;
A history of psychotropic drug abuse or have a mental disorder;
Any severe and/or uncontrolled disease;
Has received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks before the first dose;
Has received Chinese patent medicines with anti-tumor indications that National Medical Products Administration (NMPA) approved within 2 weeks before the first dose;
Has received CDC7 inhibitors;
Pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage;
Brain metastases ;
Has participated in other clinical studies within 4 weeks before the first dose;
According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jihui Hao, Doctor
Phone
022-23340123
Email
haojihui@tjmuch.com
Facility Information:
Facility Name
Tianjin Medical University Cancer Institution & Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300181
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jihui Hao, Doctor
Phone
022-23340123
Email
haojihui@tjmuch.com
12. IPD Sharing Statement
Learn more about this trial
A Clinical Study of TQB3824 in Subjects With Advanced Cancer
We'll reach out to this number within 24 hrs